**B01 Biological consequences of histone mutations in the mammalian brain.** Lawryn Kasper, St Jude Children's Research Hospital, Memphis, TN, United States.

**B02 The role of chromatin remodeler protein ARID1a in ovarian clear cell carcinoma.** Ranjani Lakshminarasimhan, University of Southern California, Los Angeles, CA, United States.

**B03 Identification of Epigenetic Regulated Genes through Simultaneous Analysis of DNA Methylation and Chromatin Structure in Uncultured Tumors.** Gangning Liang, USC Norris Comprehensive Cancer Center, Los Angeles, CA, United States.

**B04 Promoter DNA methylation is potentially associated with metastatic of pancreatic cancer.** Huey-Jen Lin, University of Delaware, Newark, DE, United States.

**B05 WHSC1L1 and estrogen-independent activation of estrogen receptor-alpha (ERα) in 8p11 amplicon-bearing cell lines.** Jamie Mills, Medical University of South Carolina, Charleston, SC, United States.

**B06 Understanding of the ovarian endometriosis and gene expression functions in neoplastic transformation.** Janice Monteiro, Ponce Health Sciences University, Ponce, PR, United States.

**B07 Gene alterations associated with clinical characteristics of bladder cancer.** Mike Nickerson, National Cancer Institute, Frederick, MD, United States.

**B08 Space radiation exposure induces stable epigenome alterations relevant to human lung cancer.** Doris Powell, Emory University, Atlanta, GA, United States.

**B09 Identification of a renal CpG island methylator phenotype (R-CIMP) in kidney tumors associated with germline mutations of FH and SDHB.** Christopher Ricketts, Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.

**B10 Increased expression of EZH2 and TOP2A predicts for a poorer prognostic outcome in Genitourinary Cancers.** Spencer Rosario, Roswell Park Cancer Institute, Buffalo, NY, United States.

**B11 Snf-ing out Crosstalk between Chromatin Remodeling Enzymes.** John Runge, University of North Carolina, Chapel Hill, NC, United States.

**B12 H3-K27M is a negative prognostic marker in high and low grade pediatric thalamic glioma.** Scott Ryall, Hospital for Sick Children, Toronto, Ontario, Canada.

**B13 Genomic mistargeting of p63 drives the cancer phenotype in head and neck squamous cell carcinoma.** Isha Sethi, State University of New York at Buffalo, Buffalo, NY, United States.

**B14 Use of DNA Methylation in Circulating Free DNA as a Potent Biomarker for Pancreatic Cancer Detection.** Keiko Shinjo, Nagoya City University, Nagoya, Japan.
B15 PBRM1 deficiency in renal cell carcinoma alters HIF-mediated gene expression. Mariesa Slaughter, University of North Carolina-Chapel Hill, Chapel Hill, NC, United States.

B16 Detection of prostate cancer associated DNA hypermethylation in diagnostic needle biopsies: Insight into field effects and heterogeneity. Karina Soerensen, Aarhus University Hospital, Aarhus, Denmark.

B17 Epigenetic regulation of NOTCH oncogenic signaling in breast cancer. Barbara Stefanska, Purdue University, West Lafayette, IN, United States.

B18 Chronic cigarette smoke exposure of bronchial epithelial cells induces progressive epigenomic changes leading to early steps of transformation. Michelle Vaz, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, United States.

B19 Genome-wide integrated epigenomics identifies FZD-X as novel modulator for platinum sensitivity in high grade serous ovarian cancer. G. Bea Wisman, University Medical Center Groningen, Groningen, Netherlands.

B20 Malignant transformation initiates a stochastic DNA methylation alteration pattern distinct from that in senescence. Wenbing Xie, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University, Baltimore, MD, United States.

B21 Integrated genomic and functional analyses of histone demethylases identify oncogenic KDM2A isoform in breast cancer. Zeng-Quan Yang, Karmanos Cancer Institute, Detroit, MI, United States.

B22 Integrative analysis of DNA methylation and gene expression data reveals complex regulation of gastric cancer. Seungyeul Yoo, Icahn School of Medicine at Mount Sinai, New York, NY, United States.

B23 Altered expressions of multiple subunits of the switch/sucrose non-fermenting (SWI/SNF) complex in Non-small cell lung cancer. Taichiro Yoshimoto, Department of integrative pathology, Jichi medical university, Shimotsuke-City, Tochigi-Pref., Japan.

B24 High-dimensional genomic data integration and bias correction using MANCIE. Chongzhi Zang, Dana-Farber Cancer Institute, Boston, MA, United States.

B25 Disruption of KMT2D-dependent histone methylation perturbs GC B cell development and cooperates with BCL2 deregulation in lymphomagenesis. Jiyuan Zhang, Columbia University, New York, NY, United States.
B26 RRx-001, a novel epigenetic modulator: Resensitization to previously failed therapy in the ongoing Phase 2 colorectal cancer study, ROCKET”. Jan Scicinski, EpicentRx, Inc, Mountain View, CA, United States.

B27, PR09 EZH2 inhibitors reveal broad EZH2 dependencies in Multiple Myeloma. Shilpi Arora, Constellation Pharmaceuticals, Cambridge, MA, United States.

B28 BET bromodomain inhibitors antagonize Brd4-Mediator complexes to undermine the acute myeloid leukemia cell state. Anand Bhagwat, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, United States.

B29 Inhibition of Histone deacetylases 1 and 2 (HDAC1,2) perturbs DNA replication and DNA repair in cancer cells: Implications in mechanism-based therapeutic strategies. Srividya Bhaskara, Huntsman Cancer Institute, Salt Lake City, UT, United States.


B32 Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Katherine Chiappinelli, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, United States.

B33 Sensitivity to BET and HDAC inhibitors in a TCF3-PBX1 driven acute lymphoblastic leukemia. Samuli Eldfors, Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki, Finland.

B34 Global histone modifications define early stress induced drug tolerance in cancer. Abdullah Al Emran, Dermatology Research Centre, Translational Research Institute, University of Queensland, Woolloongabba, Queensland, Australia.

B35, PR04 Targeting super-enhancer driven oncogene transcription through cyclin-dependent kinase inhibitors. Rani George, Dana-Farber Cancer Institute, Boston, MA, United States.

B36, PR11 A bromodomain cassette exchange strategy establishes that on-target chemical inhibition of BRD9 limits leukemia cell proliferation. Anja Hohmann, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, United States.

B37 The histone deacetyase inhibitor panobinostat sensitizes cyclin E-amplified ovarian cancer cells to poly ADP ribose polymerase inhibitors via E2F1 downregulation. Dineo Khabele, Vanderbilt University Medical Center, Nashville, TN, United States.
Poster Session B
Saturday, September 26, 2015
4:30 p.m.–6:30 p.m. 
Overlook

B38, PR10 A DNA Hypomethylation Signature Predicts Novel Anti-Tumor Activity of LSD1 Inhibition in SCLC. Helai Mohammad, GlaxoSmithKline, Collegeville, PA, United States.

B39 BRD4 inhibition improves the efficacy of ABT-199 in T-cell acute lymphoblastic leukemia. Sofie Peirs, Center for Medical Genetics, Ghent University, Ghent, Belgium.

B40 WEE1 inhibition selectively kills histone H3K36me3-deficient cancers by dNTP starvation. Sophia Pfister, CRUK MRC Oxford Institute for Radiation Oncology, Oxford, United Kingdom.

B41 Targeting Androgen-Independent Prostate Cancer Through Epigenetic Reprogramming. LOREDANA PUCA, Weill Cornell Medical College, New York, NY, United States.

B42 Decitabine specifically targets genes that gain DNA methylation and lose expression in cancer and can be combined with histone methylation inhibitors for increased efficacy. Takahiro Sato, Temple University, Philadelphia, PA, United States.

B43 Dose and context-dependent roles for Arid1a in liver tumorigenesis. Xuxu Sun, UTsouthwestern medical center, Dallas, TX, United States.

B44 Accelerated mouse colorectal cancer progression in the presence of EHMT2 overexpression. Kang-Yu Tai, Genome and Systems Biology Degree Program, National Taiwan University and Academia Sinica, Taipei, Taiwan.

B45 Therapeutic potential of PRMT5 inhibition in breast cancer. Christine Thompson, GSK, Collegeville, PA, United States.

B46 Epigenetic and molecular sensitivity landscape of Neuroblastoma identifies vulnerability to SETD8 inhibitor. Veronica Veschi, NIH, Bethesda, MD, United States.

B47 A high-throughput screen to discover inhibitors of aberrant chromatin accessibility. Aminah Wali, University of North Carolina, Chapel Hill, NC, United States.

B48 Epigenetic reprogramming of mitochondrial and metabolic functions plays a key role in arginine-deprivation based cancer therapy. Hung-Jung Wang, Institute of Molecular and Genomic Medicine, National Health Research Institutes, Miaoli, Taiwan.


B50 A phenotypic screen to identify novel potential epigenetic anti-cancer drugs from natural compounds. Hanghang Zhang, Fels Institute for Cancer Research, Temple University School of Medicine, Philadelphia, PA, United States.
B51 The pan deacetylase inhibitor panobinostat shows cytotoxic activity as monotherapy and synergism with topoisomerase inhibitors in cervical cancer cells. Lubna Wasim, Dr. B. R. Ambedkar Center for Biomedical Research, University of Delhi, Delhi, India.